Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.75 |
| ▸ | HTR3B | O95264 | 2/20 | 0.75 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.75 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.75 |
| ▸ | HTR5A | P47898 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | DRD4 | P21917 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mezacopride SCHEMBL7278137 | 1.00 | HTR3A (0.75) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Mezacopride SCHEMBL9601284 | 1.00 | HTR3A (0.75) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Mezacopride SCHEMBL678003 | 1.00 | HTR3A (0.75) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Mezacopride SCHEMBL10517254 | 0.99 | MAPK1 (0.74) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| SCHEMBL10690911 | 0.90 | HTR3A (0.74) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL7278968 | 0.89 | MAPK1 (0.71) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| (R)Zacopride SCHEMBL5387843 | 0.86 | HTR3A (1.00) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL5373467 | 0.86 | HTR3A (1.00) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL29567897 | 0.86 | HTR3A (1.00) | HTR3ACYP2D6HTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL16003 | 0.86 | HTR3A (1.00) | HTR3ACYP2D6HTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501061-B | As the macrocylc compound of antiviral | MSD ITALIA S.R.L. (IT) | 2016-03-09 | — | — | CN | claimed |
| CN-105001219-A | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME | 2015-10-28 | — | — | CN | claimed |
| CN-104718004-A | Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME | 2015-06-17 | — | — | CN | claimed |
| CN-103476258-A | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents | MERCK SHARP & DOHME | 2013-12-25 | — | — | CN | claimed |
| EP-0190920-B1 | METHOD OF ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY WITH ARYLAMIDO (AND ARYLTHIOAMIDO)AZABICYCLOALKANES | SYNTHELABO (FR) | 1993-05-05 | — | — | EP | claimed |
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | claimed |
| EP-0306345-B1 | 2-ALKOXY-N-(1-AZABICYCLO(2.2.2)-OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES HAVING AN ANTISCHIZOPHRENIC ACTIVITY | SYNTHELABO (FR) | 1993-04-14 | — | — | EP | claimed |
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | claimed |
| EP-0272052-B1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-07-08 | — | — | EP | claimed |
| US-4908370-A | Antianxiety agents | A. H. ROBBINS COMPANY, INC. (US) | 1990-03-13 | — | — | US | claimed |
| US-4863919-A | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-09-05 | — | — | US | claimed |
| EP-0327335-A1 | Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency | SYNTHELABO (FR) | 1989-08-09 | — | — | EP | claimed |
| EP-0306345-A2 | 2-Alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity | SYNTHELABO (FR) | 1989-03-08 | — | — | EP | claimed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | claimed |
| US-4717563-A | 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | A. H. ROBINS COMPANY, INC. (US) | 1988-01-05 | — | — | US | claimed |
| EP-0240180-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs | SYNTHELABO (FR) | 1987-10-07 | — | — | EP | claimed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | claimed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | claimed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | claimed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114340631-A | Combination for reducing serum phosphate in a patient | 阿德利克斯股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-105979959-B | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3884935-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2020237096-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | ARDELYX, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| EP-3492106-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | CHARMOT DOMINIQUE (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3030252-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| CN-101501061-B | As the macrocylc compound of antiviral | MSD ITALIA S.R.L. (IT) | 2016-03-09 | — | — | CN | disclosed |
| CN-105001219-A | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME | 2015-10-28 | — | — | CN | disclosed |
| CN-102361857-B | Can be used as the ring-type benzimidizole derivatives of antidiabetic | MERCK SHARP & DOHME CORP. (US) | 2015-09-16 | — | — | CN | disclosed |
| CN-101928326-B | Substitution five-heterocyclic alkyl aminoacyl compound and application thereof | INST PHARM & TOXICOLOGY AMMS | 2015-07-08 | — | — | CN | disclosed |
| CN-104718004-A | Novel azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME | 2015-06-17 | — | — | CN | disclosed |
| WO-2015021358-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | CHARMOT DOMINIQUE (US) | 2015-02-12 | — | — | WO | disclosed |
| CN-103476258-A | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents | MERCK SHARP & DOHME | 2013-12-25 | — | — | CN | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011063115-A1 | COMBINATION OF NOOTROPIC AGENT WITH ONE OR MORE NEUROGENIC OR NEUROGENIC SENSITIZING AGENTS FOR STIMULATING OR INCREASING NEUROGENESIS | BRAINCELLS INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2258359-A2 | Neurogenesis by muscarinic receptor modulation with sabcomelin | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258357-A2 | Neurogenesis with acetylcholinesterase inhibitor | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258358-A2 | Neurogenesis with acetylcholinesterase inhibitor | Braincells, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2010099217-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | BRAINCELLS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216734-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216805-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | BRAINCELLS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100120842-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7678363-B2 | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs | BRAINCELLS INC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678808-B2 | 5 HT receptor mediated neurogenesis | BRAINCELLS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090325949-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2125017-A2 | MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL | Braincells, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-101563083-A | Combinations containing a 4-acylaminopyridine derivative | BRAINCELLS INC (US) | 2009-10-21 | — | — | CN | disclosed |
| EP-2076288-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2068872-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | Braincells, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-2066355-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2026813-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | Braincells, Inc. (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-2021000-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | Braincells, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| EP-1991212-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | Braincells, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| CN-101309682-A | Modulation of neurogenesis by pde inhibition | BRAINCELLS INC (US) | 2008-11-19 | — | — | CN | disclosed |
| WO-2008097861-A2 | MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS | BRAINCELLS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188457-A1 | Modulation of Neurogenesis with Biguanides and GSK3-beta Agents | BRAINCELLS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080171750-A1 | Modulation Of Neurogenesis With Use of Modafinil | BRAINCELLS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008086483-A2 | MODULATION OF NEUROGENESIS WITH USE OF MODAFINIL | BRAINCELLS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| EP-1942879-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | Braincells, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008083204-A2 | MODULATION OF NEUROGENESIS BY MELATONINERGIC LIGANDS | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | BRAINCELLS, INC (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1940389-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | Braincells, Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1937236-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | Braincells, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1928437-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | Braincells, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080108574-A1 | MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008039863-A2 | COMPOSITION COMPRISING A MELANOCORTIN RECEPTOR (MCR) MODULATING AGENT ALONE OR IN COMBINATION WITH A SECOND NEUROGENIC AGENT FOR TREATING NERVOUS SYSTEM DISORDERS | BRAINCELLS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008036678-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036846-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008030651-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | BRAINCELLS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | BRAINCELLS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007134077-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-1993013077-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1993-07-08 | — | — | WO | disclosed |
| EP-0190920-B1 | METHOD OF ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY WITH ARYLAMIDO (AND ARYLTHIOAMIDO)AZABICYCLOALKANES | SYNTHELABO (FR) | 1993-05-05 | — | — | EP | disclosed |
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0306345-B1 | 2-ALKOXY-N-(1-AZABICYCLO(2.2.2)-OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES HAVING AN ANTISCHIZOPHRENIC ACTIVITY | SYNTHELABO (FR) | 1993-04-14 | — | — | EP | disclosed |
| EP-0353372-B1 | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1993-02-03 | — | — | EP | disclosed |
| EP-0190915-B1 | Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides | SYNTHELABO (FR) | 1992-10-28 | — | — | EP | disclosed |
| EP-0327335-B1 | ARYLAMIDO(AND ARYLTHIOAMIDO)-AZABICYCLOALKANES FOR ENHANCING MEMORY OR CORRECTING MEMORY DEFICIENCY | SYNTHELABO (FR) | 1992-10-14 | — | — | EP | disclosed |
| EP-0272052-B1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-07-08 | — | — | EP | disclosed |
| US-5025022-A | Method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-06-18 | — | — | US | disclosed |
| US-5017580-A | Memory enhancing-R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-05-21 | — | — | US | disclosed |
| US-4908370-A | Antianxiety agents | A. H. ROBBINS COMPANY, INC. (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0353372-A1 | Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
| EP-0353371-A1 | Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
| US-4877794-A | 2-Alkoxy-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-31 | — | — | US | disclosed |
| US-4870181-A | AMIDATION OF 3-AMINOQUINUCLIDINE SALT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-09-26 | — | — | US | disclosed |
| US-4863919-A | Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0327335-A1 | Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency | SYNTHELABO (FR) | 1989-08-09 | — | — | EP | disclosed |
| EP-0311724-A1 | Anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1989-04-19 | — | — | EP | disclosed |
| EP-0306345-A2 | 2-Alkoxy-n-(1-azabicyclo(2.2.2)-oct-3-yl) benzamides and thiobenzamides having an antischizophrenic activity | SYNTHELABO (FR) | 1989-03-08 | — | — | EP | disclosed |
| EP-0272052-A1 | Anxiolytic-N-(1-Azabicyclo[2.2.2]Oct-3-yl) Benzamides and Thobenzamides | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-06-22 | — | — | EP | disclosed |
| US-4722834-A | Method of using 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide-N-oxides to control emesis caused by anticancer drugs | A. H. ROBINS COMPANY, INCORPORATED (US) | 1988-02-02 | — | — | US | disclosed |
| US-4717563-A | 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | A. H. ROBINS COMPANY, INC. (US) | 1988-01-05 | — | — | US | disclosed |
| EP-0240180-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamides and thiobenzamides in the alleviation of emesis caused by non-platinum anticancer drugs | SYNTHELABO (FR) | 1987-10-07 | — | — | EP | disclosed |
| EP-0237281-A1 | 2-alkoxy-N-(1-azabicyclo[2.2.2]-oct-3-yl) benzamide-N-oxides in the control of emesis caused by anticancer drugs | SYNTHELABO (FR) | 1987-09-16 | — | — | EP | disclosed |
| EP-0190920-A2 | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)azabicycloalkanes | SYNTHELABO (FR) | 1986-08-13 | — | — | EP | disclosed |
| US-4605652-A | ALZHEIMER'S DISEASE; SENILITY | A. H. ROBINS COMPANY, INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4593034-A | 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |
| EP-0158532-A2 | Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity. | SYNTHELABO (FR) | 1985-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (26 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR3A 991/4885CYP2D6 2392/4885HTR3E 730/4885 |
| US-20080188457-A1 | Modulation of Neurogenesis with Biguanides and GSK3-beta Agents | PYGB, DCX, GSK3B | HTR3A 1876/4885CYP2D6 4815/4885HTR3E 2053/4885 |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR3A 353/4885CYP2D6 4629/4885HTR3E 504/4885 |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | HTR3A 574/4885CYP2D6 4846/4885HTR3E 1038/4885 |
| US-20100120842-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR3A 353/4885CYP2D6 4629/4885HTR3E 504/4885 |
| US-20080108574-A1 | MELANOCORTIN RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | MC1R, MC3R, MC5R | HTR3A 238/4885CYP2D6 4468/4885HTR3E 367/4885 |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | HMGCR, DCX, SREBF1 | HTR3A 2940/4885CYP2D6 4549/4885HTR3E 3228/4885 |
| US-20070270449-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | HTR3A 13/4885CYP2D6 4342/4885HTR3E 20/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR3A 13/4885CYP2D6 4559/4885HTR3E 20/4885 |
| US-20200368223-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR3A 1919/4885CYP2D6 4064/4885HTR3E 1253/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | HTR3A 3141/4885CYP2D6 4864/4885HTR3E 2780/4885 |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | HTR3A 1211/4885CYP2D6 4641/4885HTR3E 1735/4885 |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | PPARG, PPARA, PPARD | HTR3A 1384/4885CYP2D6 4662/4885HTR3E 1954/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | HTR3A 1245/4885CYP2D6 4791/4885HTR3E 1685/4885 |
| US-20090325949-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR5A, HTR6, GAP43 | HTR3A 13/4885CYP2D6 4342/4885HTR3E 20/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | HTR3A 991/4885CYP2D6 2392/4885HTR3E 730/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR3A 1919/4885CYP2D6 4064/4885HTR3E 1253/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | HTR3A 384/4885CYP2D6 4660/4885HTR3E 442/4885 |
| US-20100216734-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, NGF | HTR3A 536/4885CYP2D6 4821/4885HTR3E 844/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | HTR3A 353/4885CYP2D6 4629/4885HTR3E 504/4885 |
| US-20080064671-A1 | COMBINATIONS CONTAINING A 4-ACYLAMINOPYRIDINE DERIVATIVE | GRIN2C, COQ8A, GRIN2D | HTR3A 1152/4885CYP2D6 1652/4885HTR3E 1113/4885 |
| US-20080171750-A1 | Modulation Of Neurogenesis With Use of Modafinil | BDNF, DCX, NTRK2 | HTR3A 326/4885CYP2D6 3493/4885HTR3E 380/4885 |
| US-20200038475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR3A 991/4885CYP2D6 2392/4885HTR3E 730/4885 |
| US-20080167363-A1 | Modulation of Neurogenesis By Melatoninergic Agents | MTNR1A, GAP43, DCX | HTR3A 156/4885CYP2D6 4451/4885HTR3E 242/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | HTR3A 1292/4885CYP2D6 4673/4885HTR3E 1265/4885 |
| US-20100216805-A1 | MODULATION OF NEUROGENESIS USING D-CYCLOSERINE COMBINATIONS | GAP43, DCX, CHAT | HTR3A 1606/4885CYP2D6 4625/4885HTR3E 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.